Autologous transplant in multiple myeloma with an augmented conditioning protocol

References

• Harousseau JL, Moreau P. Autologous hematopoietic stem cell transplantation for multiple myeloma. New Engl J Med 2009;360: 2645–2654.
   PubMed Web of Science ®Google Scholar
• Moreau P, Attal M, Harousseau JL. New developments in conditioning regimens before auto-SCT in multiple myeloma. Bone Marrow Transplant 2011;46:911–915.
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91–97.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Paz-Ares L, Milan S, et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994;12:759–763.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Alexanian R, Przepiorka D, et al. Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood 1993;82:2324–2328.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Delasalle KB, Champlin R, et al. Cyclophosphamide and etoposide therapy with GM-CSF for VAD-resistant multiple myeloma. Br J Haematol 1993;83:240–244.
   PubMed Web of Science ®Google Scholar
• Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m2 melphalan and 8Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimen for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 trial. Blood 2002;99:731–735.
   PubMed Web of Science ®Google Scholar
• Jones RJ, Lee KS, Beschorner WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987;44:778–783.
   PubMed Web of Science ®Google Scholar
• Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–1473.
   PubMed Web of Science ®Google Scholar
• Moreau P, Milpied N, Mahé B, et al. Melphalan 220 mg/m2 followed by peripheral stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant 1999;23: 1003–1006.
   PubMed Web of Science ®Google Scholar
• Philips GL, Meisenberg BR, Reece DE, et al. Activity of single-agent melphalan 220 to 300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma. Bone Marrow Transplant 2004;10:473–483.
   Web of Science ®Google Scholar
• Moreau P, Harousseau JL, Wijdenes J, et al. A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. Br J Haematol 2000;109:661–664.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Bruno B, et al. Melphalan 200 mg/m2 vs. melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective multicenter phase 3 study. Blood 2010;115:1873–1879.
   PubMed Web of Science ®Google Scholar
• Carreras E, Rosinol L, Terol MJ, et al. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients. Biol Blood Marrow Transplant 2007;13:1448–1454.
   PubMed Web of Science ®Google Scholar
• Lahuerta JJ, Mateos MV, Martinez-Lopez J, et al. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Haematologica 2010;95:1913–1920.
   PubMed Web of Science ®Google Scholar
• Donato ML, Aleman A, Champlin RE, et al. High-dose topotecan, melphalan and cyclophosphamide with stem cell support: a new regimen for the treatment of multiple myeloma. Leuk Lymphoma 2004;45:755–759.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Alexanian R, Przepiorka D, et al. Thiotepa, busulfan and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood 1993;82:2324–2328.
   PubMed Web of Science ®Google Scholar
• Bladé J, Kyle RA, Greipp PR. Multiple myeloma in patients younger than 30 years. Report of 10 cases and review of the literature.. Arch Intern Med 1996;156:1463–1468.
   PubMed Web of Science ®Google Scholar
• Bladé J, Kyle RA. Multiple myeloma in young patients: clinical presentation and treatment approach. Leuk Lymphoma 1998;30: 493–501.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Durie BG, Bolejack V, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10,549 patients from the International Myeloma Working Group. Blood 2008;111:4039–4047.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906–917.
   PubMed Web of Science ®Google Scholar
• Roussel M, Moreau P, Huynh A, et al. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood 2010;115:32–37.
   PubMed Web of Science ®Google Scholar